Retatrutide is not yet commercially available, meaning current pricing reflects the grey market peptide landscape rather than pharmaceutical pricing
For the newer GLP-1 medications, it would be useful to look at whether there are genetic variants, like the variants in PAM, that explain poor responders to their medications. For now, the mechanism driving GLP-1 resistance remains unresolved, but it is likely complex and multifactorial, Gloyn said
Novo Nordisk submitted an NDA (new drug application) to the FDA on December 18, 2025, which is the formal step companies take when seeking approval for a medication to be marketed for public use
The choice between semaglutide and tirzepatide depends on factors like efficacy preferences, side effect profiles , insurance coverage, and provider recommendation rather than BMI differences